Characterization of Hepatitis C Virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5494-5502

  Le Pogam, S ^a   Yan, J M ^a   Chhabra, M ^b,d   Ilnicka, M ^a   Kang, H ^b,e   Kosaka, A ^b,f   Ali, S ^b,g   Chin, D J ^a   Shulman, N S ^c   Smith, P ^a   Klumpp, K ^a   Najera I ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b Roche   (United States)

^c GENENTECH INC   (United States)

^d GLAXOSMITHKLINE   (United States)

^e Alios BioPharma Inc   (United States)

^f Optivia Biotechnology Inc   (United States)

^g Pharmaceutical Development Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DANOPREVIR; MERICITABINE; PLACEBO;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SENSITIVITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; VIRUS CHARACTERIZATION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LACTAMS; MUTATION; PLACEBOS; RNA, VIRAL; SULFONAMIDES; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84868029979     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01035-12     Document Type: Article

References (42)

1. Ali S, et al. 2008. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob. Agents Chemother. 52:4356-4369.
2. Chayama K, et al. 2012. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55:742-748.
3. Forestier N, et al. 2011. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J. Hepatol. 54:1130-1136.
4. Forestier N, et al. 2011. Antiviral activity of danoprevir (ITMN-191/ RG7227)in combination with pegylated interferon alpha-2a and ribavirin in patients with hepatitis C. J. Infect. Dis. 204:601-608.
5. Forestier N, et al. 2007. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46:640-648.
6. Gane EJ, et al. 2012. Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatmentnaive HCV genotype-1 infected patients. J. Hepatol. 56(Suppl S2):S555- S556.
7. Gane EJ, et al. 2010. Oral combination therapy with a nucleoside poly-merase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376:1467-1475.
8. Gane EJ, et al. 2011. Once daily PSI-7977 plus RBV: pegylated interferonalfa not required for complete rapid viral response in treatment-naive patients HCV GT2 or GT3, abstr 34. 54(Suppl):377A.
9. Gaudieri S, et al. 2009. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 49: 1069-1082.
10. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. 2011. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54:1433-1444.
11. Jacobson IM, et al. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364:2405-2416.
12. Jensen DM, et al. 2010. High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: planned week 12 interim analysis from the PROPEL study. Hepatology 52(Suppl 1):360A.
13. Kieffer TL, et al. 2007. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46:631-639.
14. Kuntzen T, et al. 2008. Naturally occurring dominant resistance mutationsto hepatitisC virus protease and polymerase inhibitors intreatment-naïve patients. Hepatology 48:1769-1778.
15. Kwo P, et al. 2010. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376:705-716.
16. Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TLML, KA, McHutchison JG. 2008. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J. Hepatol. 49:163-169.
17. Lenz O, et al. 2011. Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with PEG/IFN alpha-2a/ ribavirin. J. Hepatol. 54(Suppl 1):S482-S483.
18. Lenz O, et al. 2010. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob. Agents Chemother. 54: 1878-1887.
19. Le Pogam S, et al. 2010. RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J. Infect. Dis. 202:1510-1519.
20. Le Pogam S, et al. 2008. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 61:1205-1216.
21. Le Pogam S, et al. 2010. No evidence of drug resistance or baseline S282T resistance mutation among GT1 and GT4 HCV infected patients on nucleoside polymerase inhibitor RG7128 and Peg-IFN-/RBV combination treatment for up to 12 weeks: interim analysis from the PROPEL study. Hepatology 52(Suppl 1):701-702A.
22. Lim SR, et al. 2012. Virologic escape during danoprevir (ITMN-191/ RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrob. Agents Chemother. 56:271-279.
23. Lok AS, et al. 2012. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366:216-224.
24. Ma H, et al. 2007. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-deoxy-2'-fluoro-2'-C- methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species. J. Biol. Chem. 282:29812-29820.
25. McCown M, Rajyaguru S, Kular S, Cammack N, Najera I. 2009. Suppression of in vitro resistance development after treatment of the HCV replicon with NS3/4a inhibitor ITMN-191 (R7227) in combination with nucleoside inhibitor R7128 or R1626. J. Hepatol. 50(Suppl 1):S349.
26. Merck & Co. Inc. 2011. Victrelis (boceprevir) prescribing information. Merck & Co. Inc., Whitehouse Station, NJ.http://www.accessdata. fda.gov/drugsatfda-docs/label/2011/202258lbl.pdf.
27. Migliaccio G, et al. 2003. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278:49164-49170.
28. Pawlotsky JM. 2011. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 53:1742-1751.
29. Pockros P, et al. 2011. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginter-feron/ ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial. J. Hepatol. 54:S538.
30. Poordad F, et al. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364:1195-1206.
31. Reesink H, et al. 2009. Antiviral activity and safety of TMC435 combined with pegylated interferon and ribavirin in hepatitis C patients with genotype 1 who had previous exposure to TMC435. Hepatology 50(Suppl): 1024A.
32. Reesink HW, et al. 2006. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131:997-1002.
33. Rong L, Dahari H, Ribeiro RM, Perelson AS. 2010. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Transl. Med. 2:30ra32.
34. Sarrazin C, et al. 2007. Dynamic hepatitis C virus genotypic and pheno-typic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-1777.
35. Sarrazin C, et al. 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonre-sponders. Gastroenterology 132:1270-1278.
36. Seiwert S, et al. Sequence variation of NS3/4A in HCV replicons exposed to ITMN-191 concentrations encompassing those likely to be achieved following clinical dosing. J. Hepatol. 46(Suppl 1):S244-S245.
37. Stuyver LJ, et al. 2006. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir. Chem. Chemother. 17:79-87.
38. Susser S, et al. 2009. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50: 1709-1718.
39. Trevino A, et al. 2011. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Antivir. Ther. 16:413-416.
40. Uzgiris A, et al. High genetic barrier to HCV resistance presented by PSI-6130, abstr 83. Global Antiviral J. 3(Suppl 2):89.
41. Vertex Pharmaceuticals Ltd. 2011. Incivek (telaprevir) prescribing information. Vertex Pharmaceuticals Ltd., Cambridge, MA. http://www. Natap.org/2011/HCV/INCIVEKUSPI.pdf.
42. Zhou Y, et al. 2008. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 52:110-120.